Pharmacogenetics and cancer therapy

被引:177
作者
Relling, MV
Dervieux, T
机构
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] Univ Tennessee, Coll Pharm, Memphis, TN 38163 USA
关键词
D O I
10.1038/35101056
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pharmacogenetics is the study of how genetic variations affect drug response. These variations can affect a patient's response to cancer drugs, for which there is usually a fine line between a dosage that has a therapeutic effect and one that produces toxicity. Gaining better insight into the genetic elements of both the patient and the tumour that affect drug efficacy will eventually allow for individualized dosage determination and fewer adverse effects.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 133 条
  • [1] MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity
    Ameyaw, MM
    Regateiro, F
    Li, T
    Liu, XH
    Tariq, M
    Mobarek, A
    Thornton, N
    Folayan, GO
    Githang'a, J
    Indalo, A
    Ofori-Adjei, D
    Price-Evans, DA
    McLeod, HL
    [J]. PHARMACOGENETICS, 2001, 11 (03): : 217 - 221
  • [2] Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia
    Anderer, G
    Schrappe, M
    Brechlin, AM
    Lauten, M
    Muti, P
    Welte, K
    Stanulla, M
    [J]. PHARMACOGENETICS, 2000, 10 (08): : 715 - 726
  • [3] Ando Y, 2000, CANCER RES, V60, P6921
  • [4] Pharmacogenetic prediction of clozapine response
    Arranz, MJ
    Munro, J
    Birkett, J
    Bolonna, A
    Mancama, D
    Sodhi, M
    Lesch, KP
    Meyer, JFW
    Sham, P
    Collier, DA
    Murray, RM
    Kerwin, RW
    [J]. LANCET, 2000, 355 (9215) : 1615 - 1616
  • [5] Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4
    Ball, SE
    Scatina, JA
    Kao, J
    Ferron, GM
    Fruncillo, R
    Mayer, P
    Weinryb, I
    Guida, M
    Hopkins, PJ
    Warner, N
    Hall, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) : 288 - 294
  • [6] Ban N, 1996, CANCER RES, V56, P3577
  • [7] DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY LEADING TO THYMINE-URACILURIA - AN INBORN ERROR OF PYRIMIDINE METABOLISM
    BERGER, R
    STOKERDEVRIES, SA
    WADMAN, SK
    DURAN, M
    BEEMER, FA
    DEBREE, PK
    WEITSBINNERTS, JJ
    PENDERS, TJ
    VANDERWOUDE, JK
    [J]. CLINICA CHIMICA ACTA, 1984, 141 (2-3) : 227 - 234
  • [8] A family of drug transporters: The multidrug resistance-associated proteins
    Borst, P
    Evers, R
    Kool, M
    Wijnholds, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16): : 1295 - 1302
  • [9] THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME
    BOSMA, PJ
    CHOWDHURY, JR
    BAKKER, C
    GANTLA, S
    DEBOER, A
    OOSTRA, BA
    LINDHOUT, D
    TYTGAT, GNJ
    JANSEN, PLM
    ELFERINK, RPJO
    CHOWDHURY, NR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) : 1171 - 1175
  • [10] Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors
    Carling, T
    Rastad, J
    Åkerström, G
    Westin, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07) : 2255 - 2259